1
|
Nwabufo CK, Aigbogun OP. The Role of Mass Spectrometry Imaging in Pharmacokinetic Studies. Xenobiotica 2022; 52:811-827. [PMID: 36048000 DOI: 10.1080/00498254.2022.2119900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
Although liquid chromatography-tandem mass spectrometry is the gold standard analytical platform for the quantification of drugs, metabolites, and biomarkers in biological samples, it cannot localize them in target tissues.The localization and quantification of drugs and/or their associated metabolites in target tissues is a more direct measure of bioavailability, biodistribution, efficacy, and regional toxicity compared to the traditional substitute studies using plasma.Therefore, combining high spatial resolution imaging functionality with the superior selectivity and sensitivity of mass spectrometry into one analytical technique will be a valuable tool for targeted localization and quantification of drugs, metabolites, and biomarkers.Mass spectrometry imaging (MSI) is a tagless analytical technique that allows for the direct localization and quantification of drugs, metabolites, and biomarkers in biological tissues, and has been used extensively in pharmaceutical research.The overall goal of this current review is to provide a detailed description of the working principle of MSI and its application in pharmacokinetic studies encompassing absorption, distribution, metabolism, excretion, and toxicity processes, followed by a discussion of the strategies for addressing the challenges associated with the functional utility of MSI in pharmacokinetic studies that support drug development.
Collapse
Affiliation(s)
- Chukwunonso K Nwabufo
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
| | - Omozojie P Aigbogun
- Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada.,Department of Chemistry, University of Saskatchewan, Saskatoon, Canada
| |
Collapse
|
2
|
Spencer CE, Flint LE, Duckett CJ, Cole LM, Cross N, Smith DP, Clench MR. Role of MALDI-MSI in combination with 3D tissue models for early stage efficacy and safety testing of drugs and toxicants. Expert Rev Proteomics 2020; 17:827-841. [PMID: 33440126 PMCID: PMC8396712 DOI: 10.1080/14789450.2021.1876568] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 01/12/2021] [Indexed: 12/13/2022]
Abstract
Introduction: Three-dimensional (3D) cell cultures have become increasingly important materials to investigate biological processes and drug efficacy and toxicity. The ability of 3D cultures to mimic the physiology of primary tissues and organs in the human body enables further insight into cellular behavior and is hence highly desirable in early-stage drug development. Analyzing the spatial distribution of drug compounds and endogenous molecules provides an insight into the efficacy of a drug whilst simultaneously giving information on biological responses. Areas Covered: In this review we will examine the main 3D cell culture systems employed and applications, which describe their integration with mass spectrometry imaging (MSI). Expert Opinion: MSI is a powerful technique that can map a vast range of molecules simultaneously in tissues without the addition of labels that can provide insights into the efficacy and safety of a new drug. The combination of MSI and 3D cell cultures has emerged as a promising tool in early-stage drug analysis. However, the most common administration route for pharmaceutical drugs is via oral delivery. The use of MSI in combination with models of the GI tract is an area that has been little explored to date, the reasons for this are discussed.
Collapse
Affiliation(s)
- Chloe E Spencer
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| | - Lucy E Flint
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| | - Catherine J Duckett
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| | - Laura M Cole
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| | - Neil Cross
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| | - David P Smith
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| | - Malcolm R Clench
- Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
| |
Collapse
|
3
|
Goodwin RJA, Takats Z, Bunch J. A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery. SLAS DISCOVERY 2020; 25:963-976. [PMID: 32713279 DOI: 10.1177/2472555220941843] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
During the past decade, mass spectrometry imaging (MSI) has become a robust and versatile methodology to support modern pharmaceutical research and development. The technologies provide data on the biodistribution, metabolism, and delivery of drugs in tissues, while also providing molecular maps of endogenous metabolites, lipids, and proteins. This allows researchers to make both pharmacokinetic and pharmacodynamic measurements at cellular resolution in tissue sections or clinical biopsies. Despite drug imaging within samples now playing a vital role within research and development (R&D) in leading pharmaceutical companies, however, the challenges in turning compounds into medicines continue to evolve as rapidly as the technologies used to discover them. The increasing cost of development of new and emerging therapeutic modalities, along with the associated risks of late-stage program attrition, means there is still an unmet need in our ability to address an increasing array of challenging bioanalytical questions within drug discovery. We require new capabilities and strategies of integrated imaging to provide context for fundamental disease-related biological questions that can also offer insights into specific project challenges. Integrated molecular imaging and advanced image analysis have the opportunity to provide a world-class capability that can be deployed on projects in which we cannot answer the question with our battery of established assays. Therefore, here we will provide an updated concise review of the use of MSI for drug discovery; we will also critically consider what is required to embed MSI into a wider evolving R&D landscape and allow long-lasting impact in the industry.
Collapse
Affiliation(s)
- Richard J A Goodwin
- Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.,Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, UK
| | - Zoltan Takats
- Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK.,The Rosalind Franklin Institute, Oxfordshire, UK
| | - Josephine Bunch
- Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK.,The Rosalind Franklin Institute, Oxfordshire, UK.,National Physical Laboratory, Teddington, London, UK
| |
Collapse
|
4
|
Takeo E, Shimma S. Development of quantitative imaging mass spectrometry (q
-IMS) for drug visualization using animal tissues. SURF INTERFACE ANAL 2018. [DOI: 10.1002/sia.6537] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Emi Takeo
- Department of Biotechnology, Graduate School of Engineering; Osaka University; Suita 565-0871 Japan
| | - Shuichi Shimma
- Department of Biotechnology, Graduate School of Engineering; Osaka University; Suita 565-0871 Japan
| |
Collapse
|
5
|
Barré FPY, Flinders B, Garcia JP, Jansen I, Huizing LRS, Porta T, Creemers LB, Heeren RMA, Cillero-Pastor B. Derivatization Strategies for the Detection of Triamcinolone Acetonide in Cartilage by Using Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Anal Chem 2016; 88:12051-12059. [PMID: 28193015 DOI: 10.1021/acs.analchem.6b02491] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Osteoarthritis (OA), characterized by degeneration of the cartilaginous tissue in articular joints, severely impairs mobility in many people worldwide. The degeneration is thought to be mediated by inflammatory processes occurring in the tissue of the joint, including the cartilage. Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatments employed to ameliorate the inflammation and pain that characterizes OA. However, the penetration and distribution of TAA into the avascular cartilage is not well understood. We employed matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), which has been previously used to directly monitor the distribution of drugs in biological tissues, to evaluate the distribution of TAA in human cartilage after in vitro incubation. Unfortunately, TAA is not easily ionized by regular electrospray ionization (ESI) or MALDI. To overcome this problem, we developed an on-tissue derivatization method with Girard's reagent T (GirT) in human incubated cartilage being able to study its distribution and quantify the drug abundance (up to 3.3 ng/μL). Our results demonstrate the depth of penetration of a corticosteroid drug in human OA cartilage using MALDI-MSI.
Collapse
Affiliation(s)
- Florian P Y Barré
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University , Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Bryn Flinders
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University , Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - João P Garcia
- University Medical Centre (UMC) Utrecht , Orthopedics Department, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
| | - Imke Jansen
- University Medical Centre (UMC) Utrecht , Orthopedics Department, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
| | - Lennart R S Huizing
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University , Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Tiffany Porta
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University , Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Laura B Creemers
- University Medical Centre (UMC) Utrecht , Orthopedics Department, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
| | - Ron M A Heeren
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University , Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Berta Cillero-Pastor
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University , Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| |
Collapse
|
6
|
Abstract
During the last decade, lateral and temporal localization of drug compounds and their metabolites have been demonstrated and dynamically developed using MS imaging. The pharmaceutical industry has recognized the potential of the technology that provides simultaneous distribution and quantitative data. In this review, we present the latest technological achievements and summarize applications of drug imaging focusing on studies about metabolites by MALDI-MS imaging. We also introduce potential areas with pharmaceutical applications that are currently under exploration, including pharmacological, toxicological characterizations and metabolic enzyme localization in comparison with drug and metabolite distribution.
Collapse
|
7
|
Bodzon-Kulakowska A, Suder P. Imaging mass spectrometry: Instrumentation, applications, and combination with other visualization techniques. MASS SPECTROMETRY REVIEWS 2016; 35:147-69. [PMID: 25962625 DOI: 10.1002/mas.21468] [Citation(s) in RCA: 118] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Accepted: 01/23/2015] [Indexed: 05/18/2023]
Abstract
Imaging Mass Spectrometry (IMS) is strengthening its position as a valuable analytical tool. It has unique ability to identify structures and to unravel molecular changes that occur in the precisely defined part of the sample. These unique features open new possibilities in the field of various aspects of biological research. In this review we briefly discuss the main imaging mass spectrometry techniques, as well as the nature of biological samples and molecules, which might be analyzed by such methodology. Moreover, a novel approach, where different analytical techniques might be combined with the results of IMS study, is emphasized and discussed. With such a fast development of IMS and related methods, we can foresee the promising future of this technique.
Collapse
Affiliation(s)
- Anna Bodzon-Kulakowska
- Department of Biochemistry and Neurobiology, Faculty of Materials Sciences and Ceramics, AGH University of Science and Technology, 30-059 Krakow, Poland
| | - Piotr Suder
- Department of Biochemistry and Neurobiology, Faculty of Materials Sciences and Ceramics, AGH University of Science and Technology, 30-059 Krakow, Poland
- Academic Centre for Materials and Nanotechnology (ACMiN), AGH University of Science and Technology, 30-059 Krakow, Poland
| |
Collapse
|
8
|
Handberg E, Chingin K, Wang N, Dai X, Chen H. Mass spectrometry imaging for visualizing organic analytes in food. MASS SPECTROMETRY REVIEWS 2015; 34:641-58. [PMID: 24687728 DOI: 10.1002/mas.21424] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Revised: 02/18/2014] [Accepted: 02/18/2014] [Indexed: 05/27/2023]
Abstract
The demand for rapid chemical imaging of food products steadily increases. Mass spectrometry (MS) is featured by excellent molecular specificity of analysis and is, therefore, a very attractive method for chemical profiling. MS for food imaging has increased significantly over the past decade, aided by the emergence of various ambient ionization techniques that allow direct and rapid analysis in ambient environment. In this article, the current status of food imaging with MSI is reviewed. The described approaches include matrix-assisted laser desorption/ionization (MALDI), but emphasize desorption atmospheric pressure photoionization (DAPPI), electrospray-assisted laser desorption/ionization (ELDI), probe electrospray ionization (PESI), surface desorption atmospheric pressure chemical ionization (SDAPCI), and laser ablation flowing atmospheric pressure afterglow (LA-FAPA). The methods are compared with regard to spatial resolution; analysis speed and time; limit of detection; and technical aspects. The performance of each method is illustrated with the description of a related application. Specific requirements in food imaging are discussed.
Collapse
Affiliation(s)
- Eric Handberg
- Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, Department of Applied Chemistry, East China Institute of Technology, Nanchang, 330013, P.R. China
| | - Konstantin Chingin
- Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, Department of Applied Chemistry, East China Institute of Technology, Nanchang, 330013, P.R. China
| | - Nannan Wang
- Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, Department of Applied Chemistry, East China Institute of Technology, Nanchang, 330013, P.R. China
| | - Ximo Dai
- Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, Department of Applied Chemistry, East China Institute of Technology, Nanchang, 330013, P.R. China
| | - Huanwen Chen
- Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, Department of Applied Chemistry, East China Institute of Technology, Nanchang, 330013, P.R. China
| |
Collapse
|
9
|
Liu X, Hummon AB. Mass spectrometry imaging of therapeutics from animal models to three-dimensional cell cultures. Anal Chem 2015; 87:9508-19. [PMID: 26084404 PMCID: PMC4766864 DOI: 10.1021/acs.analchem.5b00419] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Mass spectrometry imaging (MSI) is a powerful label-free technique for the investigation of the spatial distribution of molecules at complex surfaces and has been widely used in the pharmaceutical sciences to understand the distribution of different drugs and their metabolites in various biological samples, ranging from cell-based models to tissues. Here, we review the current applications of MSI for drug studies in animal models, followed by a discussion of the novel advances of MSI in three-dimensional (3D) cell cultures for accurate, efficient, and high-throughput analyses to evaluate therapeutics.
Collapse
Affiliation(s)
- Xin Liu
- Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN 46556, USA
| | - Amanda B. Hummon
- Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN 46556, USA
| |
Collapse
|
10
|
Abstract
Analysis of drug and metabolite distribution is essential for understanding of the mechanisms underlying the pharmacological or toxicological effects. MS imaging (MSI) can visualize the distribution of drugs or biological molecules in tissue sections without radiolabeling, and distinguish between the distribution of a drug and that of its metabolites in tissue sections. Therefore, it is expected to be a potent imaging technique for drug distribution studies. This article includes cases in which MSI was used to analyze drug and metabolite distribution, and discusses the impact of data obtained by MSI in drug discovery and development.
Collapse
|
11
|
Abstract
Enriched by a decade of remarkable developments, matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS) has witnessed a phenomenal expansion. Initially introduced for the mapping of peptides and intact proteins from mammalian tissue sections, MALDI IMS applications now extend to a wide range of molecules including peptides, lipids, metabolites and xenobiotics. Technology and methodology are quickly evolving to push the limits of the technique forward. Within a short period of time, numerous protocols and concepts have been developed and introduced in tissue section preparation, nonexhaustively including in situ tissue chemistries and solvent-free matrix depositions. Considering the past progress and current capabilities, this Review aims to cover the different aspects and challenges of tissue section preparation for MALDI IMS.
Collapse
|
12
|
Olsen LR, Hansen SH, Janfelt C. Distribution of terfenadine and its metabolites in locusts studied by desorption electrospray ionization mass spectrometry imaging. Anal Bioanal Chem 2014; 407:2149-58. [DOI: 10.1007/s00216-014-8292-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Revised: 10/10/2014] [Accepted: 10/22/2014] [Indexed: 01/17/2023]
|
13
|
Abstract
To fully understand the drug mechanism of action of new chemical entities, pharmacologists need to acquire confident and precise data in pharmacokinetics and in pharmacodynamics and build strong pharmacokinetic/pharmacodynamic relationships. Target engagement in evaluating new chemical entities provides the basis for treatment efficacy. Classical technologies are sometimes limited or inefficient to provide these precise data; however, label-free MS imaging technology is able to provide these molecular features, spatial distributions, quantification and metabolomics data. Important considerations for imaging biological sections are described. Various applications in pharmacology are presented across different therapeutic areas, where MS imaging answers crucial drug discovery and preclinical development needs.
Collapse
|
14
|
Swales JG, Tucker JW, Strittmatter N, Nilsson A, Cobice D, Clench MR, Mackay CL, Andren PE, Takáts Z, Webborn PJH, Goodwin RJA. Mass Spectrometry Imaging of Cassette-Dosed Drugs for Higher Throughput Pharmacokinetic and Biodistribution Analysis. Anal Chem 2014; 86:8473-80. [DOI: 10.1021/ac502217r] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- John G. Swales
- Drug Safety and Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
- Biomedical Research
Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, U.K
| | - James W. Tucker
- Drug Safety and Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Nicole Strittmatter
- Department
of Surgery and Cancer, Sir Alexander Fleming Building, Imperial College, London SW7 2AZ, U.K
| | - Anna Nilsson
- Biomolecular Imaging
and Proteomics, National Center for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala 751 05, Sweden
| | - Diego Cobice
- Department
of Surgery and Cancer, Sir Alexander Fleming Building, Imperial College, London SW7 2AZ, U.K
| | - Malcolm R. Clench
- Biomedical Research
Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, U.K
| | - C. Logan Mackay
- Department
of Surgery and Cancer, Sir Alexander Fleming Building, Imperial College, London SW7 2AZ, U.K
| | - Per E. Andren
- Biomolecular Imaging
and Proteomics, National Center for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala 751 05, Sweden
| | - Zoltán Takáts
- Department
of Surgery and Cancer, Sir Alexander Fleming Building, Imperial College, London SW7 2AZ, U.K
| | - Peter J. H. Webborn
- Drug Safety and Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Richard J. A. Goodwin
- Drug Safety and Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| |
Collapse
|
15
|
Groseclose MR, Castellino S. A mimetic tissue model for the quantification of drug distributions by MALDI imaging mass spectrometry. Anal Chem 2013; 85:10099-106. [PMID: 24024735 DOI: 10.1021/ac400892z] [Citation(s) in RCA: 141] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The full potential of imaging mass spectrometry (IMS) as a tool in drug development will not be realized until reliable quantitative information can be integrated with the molecular distributions. Here we report a novel method for the quantification of drugs in tissue sections using matrix-assisted laser desorption/ionization (MALDI) IMS. This method uses a mimetic tissue model consisting of a set of tissue homogenates spiked with a range of different drug concentrations that have been frozen into a polymer support mold. The goal of this model is to mimic a dosed tissue in its effects on analyte extraction and ion suppression. Parallel preparation and analysis of sections from the tissue model and the dosed tissues allow for the quantification of a drug's distribution. Here we detail the steps involved in constructing the model and provide proof of concept data to highlight the potential of this approach. Several figures of merit are evaluated including linearity of response, variability, and section-to-section reproducibility. Finally, the tissue model is used to quantify two different drugs, lapatinib and nevirapine, in dosed tissues from nonclinical species and the results are compared with those generated by LC-MS quantification.
Collapse
Affiliation(s)
- M Reid Groseclose
- Drug Metabolism and Pharmacokinetics, GlaxoSmithKline , Research Triangle Park, North Carolina 27709, United States
| | | |
Collapse
|
16
|
Xu H, Valenzuela N, Fai S, Figeys D, Bennett SAL. Targeted lipidomics - advances in profiling lysophosphocholine and platelet-activating factor second messengers. FEBS J 2013; 280:5652-67. [PMID: 23826908 DOI: 10.1111/febs.12423] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 06/27/2013] [Accepted: 07/01/2013] [Indexed: 12/17/2022]
Abstract
Glycerophosphocholines are the major building blocks of biological membranes. They are also precursors of low-molecular-weight second messengers with mass to charge ratios of 450-600. These messengers include lysophosphatidylcholines (LPCs) and lyso-platelet activating factors (PAFs) that may be further processed into PAFs. Often considered as a single species, LPCs, PAFs and lyso-PAFs are, in fact, families of glycerophosphocholine-derived lipids distinguished by the linkage of their sn-1 carbon chains to the phosphoglyceride backbone (ester or ether), their sn-1 carbon chain length and degree of unsaturation, and the identity of their sn-2 constituents (a hydroxyl or acetyl group). Each LPC and PAF species exhibits a different affinity for its cognate G-protein-coupled receptors, and each species elicits receptor-independent actions that play critical signalling roles. Targeted mass spectrometry-based lipidomic approaches are enabling the molecular identification and quantification of these low-abundance second messengers. Variations between datasets map the temporal landscape of second messengers available for signalling, and provide snapshots of the state of structural membrane compositional remodelling at the time of extraction. Here, we review a number of advances in lipidomic methodologies used to identify LPCs, lyso-PAFs and PAFs, and highlight how these targeted approaches are providing valuable insight into the roles played by the cellular lipidome in cell function and disease susceptibility.
Collapse
Affiliation(s)
- Hongbin Xu
- Ottawa Institute of Systems Biology, University of Ottawa, Ontario, Canada; Neural Regeneration Laboratory, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ontario, Canada
| | | | | | | | | |
Collapse
|
17
|
Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels. Histochem Cell Biol 2013; 140:93-104. [PMID: 23881163 DOI: 10.1007/s00418-013-1127-4] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2013] [Indexed: 10/26/2022]
Abstract
Mass spectrometry imaging (MSI) is a rapidly evolving technology that yields qualitative and quantitative distribution maps of small pharmaceutical-active molecules and their metabolites in tissue sections in situ. The simplicity, high sensitivity and ability to provide comprehensive spatial distribution maps of different classes of biomolecules make MSI a valuable tool to complement histopathology for diagnostics and biomarker discovery. In this review, qualitative and quantitative MSI of drugs and metabolites in tissue at therapeutic levels are discussed and the impact of this technique in drug discovery and clinical research is highlighted.
Collapse
|
18
|
Shahidi-Latham SK, Dutta SM, Prieto Conaway MC, Rudewicz PJ. Evaluation of an accurate mass approach for the simultaneous detection of drug and metabolite distributions via whole-body mass spectrometric imaging. Anal Chem 2012; 84:7158-65. [PMID: 22827834 DOI: 10.1021/ac3015142] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In drug discovery and development, in vitro absorption and metabolism assays along with in vivo pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) studies are used to evaluate a potential drug candidate. More recently, imaging mass spectrometry approaches have been successfully reported to aid in the preclinical assessment of drug candidates, resulting in the rapid and noteworthy acceptance of the technique in pharmaceutical research. Traditionally, drug distribution studies via mass spectrometric imaging (MSI) are performed as targeted MS/MS analyses, where the analytes of interest, drug and/or metabolite, are known before the imaging experiment is performed. The study presented here describes a whole-body mass spectrometric imaging (WB-MSI) approach using a hybrid MALDI-LTQ-Orbitrap-MS to detect the distribution of reserpine at 2 h post a 20 mg/kg oral dose. This study effectively demonstrates the utility of obtaining accurate mass measurements across a wide mass range combined with postprocessing tools to efficiently identify drug and metabolite distributions without the need for any a priori knowledge.
Collapse
|
19
|
Prideaux B, Stoeckli M. Mass spectrometry imaging for drug distribution studies. J Proteomics 2012; 75:4999-5013. [DOI: 10.1016/j.jprot.2012.07.028] [Citation(s) in RCA: 224] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Revised: 07/15/2012] [Accepted: 07/16/2012] [Indexed: 01/13/2023]
|
20
|
Takai N, Tanaka Y, Inazawa K, Saji H. Quantitative analysis of pharmaceutical drug distribution in multiple organs by imaging mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2012; 26:1549-56. [PMID: 22638972 DOI: 10.1002/rcm.6256] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
RATIONALE Recently, the requirement for a quantitative research method using imaging mass spectrometry (IMS) to be developed has been discussed. Specifically, the simultaneous quantification of a drug in multiple organs by using whole-body sections could be insightful for the pharmaceutical industry in the study of drug distribution. METHODS Frozen whole-body sections were obtained from mice injected with raclopride, a dopamine D2 receptor selective antagonist, and coated with a matrix-assisted laser desorption/ionization (MALDI) matrix compound. The whole-body sections were then analyzed using a linear ion trap mass spectrometer equipped with a MALDI source. The concentration of raclopride in each tissue was determined using liquid chromatography/tandem mass spectrometry (LC/MS/MS). RESULTS The IMS-based signal intensity of raclopride strongly correlated with the concentration of the drug in the tissue samples (R=0.94; p <0.001) of six different organs. Furthermore, the spatial information obtained by IMS was very similar to that obtained by autoradiography, which is a traditional technique used for the study of drug distribution. CONCLUSIONS This study suggests that IMS enables the quantitative analysis of drug distribution in multiple organs simultaneously. In addition, it enhances ideal drug candidate selection in terms of efficient evaluations.
Collapse
Affiliation(s)
- Nozomi Takai
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
| | | | | | | |
Collapse
|
21
|
Eikel D, Vavrek M, Smith S, Bason C, Yeh S, Korfmacher WA, Henion JD. Liquid extraction surface analysis mass spectrometry (LESA-MS) as a novel profiling tool for drug distribution and metabolism analysis: the terfenadine example. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2011; 25:3587-96. [PMID: 22095508 DOI: 10.1002/rcm.5274] [Citation(s) in RCA: 129] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
Liquid extraction surface analysis mass spectrometry (LESA-MS) is a novel surface profiling technique that combines micro-liquid extraction from a solid surface with nano-electrospray mass spectrometry. One potential application is the examination of the distribution of drugs and their metabolites by analyzing ex vivo tissue sections, an area where quantitative whole body autoradiography (QWBA) is traditionally employed. However, QWBA relies on the use of radiolabeled drugs and is limited to total radioactivity measured whereas LESA-MS can provide drug- and metabolite-specific distribution information. Here, we evaluate LESA-MS, examining the distribution and biotransformation of unlabeled terfenadine in mice and compare our findings to QWBA, whole tissue LC/MS/MS and MALDI-MSI. The spatial resolution of LESA-MS can be optimized to ca. 1 mm on tissues such as brain, liver and kidney, also enabling drug profiling within a single organ. LESA-MS can readily identify the biotransformation of terfenadine to its major, active metabolite fexofenadine. Relative quantification can confirm the rapid absorption of terfendine after oral dosage, its extensive first pass metabolism and the distribution of both compounds into systemic tissues such as muscle, spleen and kidney. The elimination appears to be consistent with biliary excretion and only trace levels of fexofenadine could be confirmed in brain. We found LESA-MS to be more informative in terms of drug distribution than a comparable MALDI-MS imaging study, likely due to its favorable overall sensitivity due to the larger surface area sampled. LESA-MS appears to be a useful new profiling tool for examining the distribution of drugs and their metabolites in tissue sections.
Collapse
|
22
|
Koeniger SL, Talaty N, Luo Y, Ready D, Voorbach M, Seifert T, Cepa S, Fagerland JA, Bouska J, Buck W, Johnson RW, Spanton S. A quantitation method for mass spectrometry imaging. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2011; 25:503-10. [PMID: 21259359 DOI: 10.1002/rcm.4891] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
A new quantitation method for mass spectrometry imaging (MSI) with matrix-assisted laser desorption/ionization (MALDI) has been developed. In this method, drug concentrations were determined by tissue homogenization of five 10 µm tissue sections adjacent to those analyzed by MSI. Drug levels in tissue extracts were measured by liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS). The integrated MSI response was correlated to the LC/MS/MS drug concentrations to determine the amount of drug detected per MSI ion count. The study reported here evaluates olanzapine in liver tissue. Tissue samples containing a range of concentrations were created from liver harvested from rats administered a single dose of olanzapine at 0, 1, 4, 8, 16, 30, or 100 mg/kg. The liver samples were then analyzed by MALDI-MSI and LC/MS/MS. The MALDI-MSI and LC/MS/MS correlation was determined for tissue concentrations of ~300 to 60,000 ng/g and yielded a linear relationship over two orders of magnitude (R(2) = 0.9792). From this correlation, a conversion factor of 6.3 ± 0.23 fg/ion count was used to quantitate MSI responses at the pixel level (100 µm). The details of the method, its importance in pharmaceutical analysis, and the considerations necessary when implementing it are presented.
Collapse
Affiliation(s)
- Stormy L Koeniger
- Advanced Technology, GPRD, Abbott Laboratories, Abbott Park, IL 60064, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Grey AC, Gelasco AK, Section J, Moreno-Rodriguez RA, Krug EL, Schey KL. Molecular morphology of the chick heart visualized by MALDI imaging mass spectrometry. Anat Rec (Hoboken) 2010; 293:821-8. [PMID: 20186963 DOI: 10.1002/ar.21103] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Utilization of MALDI-MS (matrix-assisted laser desorption/ionization mass spectrometry) for tissue imaging is a relatively new proteomic technique that simultaneously maps the spatial distribution of multiple proteins directly within a single frozen tissue section. Here, we report the development of a methodology to apply MALDI tissue imaging to chick heart tissue sections acquired from fixed and paraffin-embedded samples. This protocol produces molecular images that can be related to the high-quality histological tissue sections. Perfused term chick hearts were fixed in acidic ethanol and embedded in paraffin wax. Tissue sections (15 microm) were collected onto conductive slides, deparaffinized with xylene, and transitioned into water with graded ethanol washes and allowed to air dry. In separate experiments, three different MALDI matrices were applied to chick heart tissue sections through repeated cycles from a glass nebulizer. Tissue sections were then analyzed by MALDI mass spectrometry using a raster step-size of 75-100 microm, and molecular images for specific m/z ratios reconstituted. MALDI tissue imaging revealed spatially resolved protein signals within single heart sections that are specific to structures or regions of the heart, for example, vessels, valves, endocardium, myocardium, or septa. Moreover, no prior knowledge of protein expression is required as is the case for immunohistochemistry and in situ hybridization methodologies. The ability to simultaneously localize a large number of unique protein signals within a single tissue section, with good preservation of histological features, provides cardiovascular researchers a new tool to give insight into the molecular mechanisms underlying normal and pathological conditions.
Collapse
Affiliation(s)
- Angus C Grey
- Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina, USA
| | | | | | | | | | | |
Collapse
|
24
|
Hsieh Y, Li F, Korfmacher WA. Mapping pharmaceuticals in rat brain sections using MALDI imaging mass spectrometry. Methods Mol Biol 2010; 656:147-158. [PMID: 20680589 DOI: 10.1007/978-1-60761-746-4_8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Matrix-assisted laser desorption/ionization-tandem mass spectrometric method (MALDI-MS/MS) has proven to be a reliable tool for direct measurement of the disposition of small molecules in animal tissue sections. As example, MALDI-MS/MS imaging system was employed for visualizing the spatial distribution of astemizole and its primary metabolite in rat brain tissues. Astemizole is a second-generation antihistamine, a block peripheral H1 receptor, which was introduced to provide comparable therapeutic benefit but was withdrawn in most countries due to toxicity risks. Astemizole was observed to be heterogeneously distributed to most parts of brain tissue slices including cortex, hippocampus, hypothalamic, thalamus, and ventricle regions while its major metabolite, desmethylastemizole, was only found around ventricle sites. We have shown that astemizole alone is likely to be responsible for the central nervous system (CNS) side effects when its exposures became elevated.
Collapse
Affiliation(s)
- Yunsheng Hsieh
- Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Kenilworth, NJ, USA
| | | | | |
Collapse
|
25
|
MALDI–tandem mass spectrometry imaging of astemizole and its primary metabolite in rat brain sections. Bioanalysis 2009; 1:299-307. [DOI: 10.4155/bio.09.27] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: Matrix-assisted laser desorption/ionization (MALDI)–tandem mass spectrometry (MS)/MS is a proven reliable tool for visualizing the spatial distribution of dosed drugs and their primary metabolites in animal tissue sections. Materials & methods: The rat brain tissue sections coated with dihydroxybenzoic acid as matrix, were analyzed by MALDI–MS/MS imaging experiments. The potential metabolites of astemizole in rat brain homogenate selected for MALDI–MS/MS imaging experiments were first identified by high-performance liquid chromatography coupled to an electrospray ionization source and a hybrid-quadrupole–linear-ion-trap mass spectrometer. Results: Astemizole was observed to be heterogeneously distributed to most parts of the brain tissue slices including the cortex, hippocampus, hypothalamic, thalamus and ventricle regions, while its major metabolite, desmethylastemizole, was only found around ventricle sites. Conclusion: The results indicated that the dosed compound alone might be responsible for the CNS side-effects when drug exposures became elevated.
Collapse
|